Comparative evaluation of the safety and efficacy of long term use of anti-cholinergic, Imidafenacin and Solifenacin, on overactive bladder: a prospective randomized trial.

Comparative evaluation of the safety and efficacy of long term use of anti-cholinergic, Imidafenacin and Solifenacin, on overactive bladder: a prospective randomized trial. - LIST study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004354

Enrollment

Registered

2010-11-10

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

Imidafenacin 0.2mg/day bid Solifenacin 5mg/day qd

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with previously untreated OAB, has urinary urgency once a week or more (Question 2 of OABSS>=2) and also has total OABSS>=3.

Exclusion criteria

Exclusion criteria: 1)Contraindication to anti-cholinergic agents. (Primary angle-closure glaucoma , urinary retention , Obstructive intestinal disease, paralytic ileus, gastrointestinal atony, myastania gravis) 2)Residual urine >=100mL. 3)Suspect of prostate cancer. 4)Active urinary tract infection. 5)Judged as being unsuitable for the trial by the researcher.

Design outcomes

Primary

Measure	Time frame
1)OABSS 2)Side effects(dry mouth, constipation, vision blurred etc)	—

Secondary

Measure	Time frame
1)King's Health Questionnaire 2)QTc interval 3)Residual urine volume	—

Countries

Japan

Contacts

Public ContactMasayoshi Zaitsu

Kanto Rosai Hospital Urology

masayoshi-zaitu@kantoh.rofuku.go.jp044-411-3131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026